Fig. 3

Wild-type mice treated with the PP2A activator AAL(s) and Tnfsf10^−/− mice were protected from increases in Mid1 mRNA, and the loss of PP2A activity and lung function induced by bleomycin. Mid-1 mRNA was downregulated in AAL(s) treated WT mice and Tnfsf10^−/− mice exposed to bleomycin (a) while PP2A activity was increased (b). The vital capacity (VC) and pressure at the peak of compliance (Cpk) were both decreased by bleomycin 21 days post exposure but Tnfsf10^−/− mice or those treated with AAL(s) were protected (c-d). n = 5–8, * p < 0.05